Intravitreal bevacizumab for choroidal neovascularization secondary to Best vitelliform macular dystrophy in a 6-year-old child

Eur J Ophthalmol. 2012 Jul-Aug;22(4):677-9. doi: 10.5301/ejo.5000095.

Abstract

Purpose: To report a young patient with choroidal neovascularization (CNV) secondary to Best vitelliform macular dystrophy (BVMD) who recovered good visual acuity with intravitreal bevacizumab (IVB).

Methods: A 6-year-old boy was noted to have diminution of vision in both eyes. His best-corrected visual acuity (BCVA) was 20/40 in the right eye (OD) and 20/160 in the left eye (OS). Detailed examination including slit-lamp biomicroscopy, fluorescein angiography, and optical coherence tomography (OCT) showed active CNV in OS. Two consecutive IVB injections (1.25 mg/0.05 mL) were given in OS.

Results: During the follow-up, OD showed minimal subretinal fluid on OCT and was treated with one injection of IVB (1.25 mg/0.05 mL). At 9 months of follow-up, OS BCVA was 20/50 and OD BCVA 20/30 with presence of scarred CNV on fundus examination and OCT in both the eyes. No drug-related ocular or systemic side effects were encountered.

Conclusions: Intravitreal bevacizumab appears to be a promising and cost-effective modality of treatment in CNV associated with BVMD with good visual recovery.

Publication types

  • Case Reports

MeSH terms

  • Angiogenesis Inhibitors / administration & dosage*
  • Antibodies, Monoclonal, Humanized / administration & dosage*
  • Bevacizumab
  • Child
  • Choroidal Neovascularization / drug therapy*
  • Choroidal Neovascularization / etiology
  • Choroidal Neovascularization / physiopathology
  • Fluorescein Angiography
  • Humans
  • Intravitreal Injections
  • Male
  • Tomography, Optical Coherence
  • Vascular Endothelial Growth Factor A / antagonists & inhibitors
  • Visual Acuity / physiology
  • Vitelliform Macular Dystrophy / complications*

Substances

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal, Humanized
  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A
  • Bevacizumab